Back to Research Home
ALNYAlnylam Pharmaceuticals Inc
Health Care · Biotechnology: Pharmaceutical Preparations · Large
$224.03−1.43%
As of 23 Oct 2026Mkt cap $35.8B
Stage 13
AVOID
Fundamentals
22.3/75
Technical
4.6/15
Independent
26.9/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −10.2%
- 3M
- −19.5%
- 6M
- −26.7%
- 1Y
- −51.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 41.6xHist median 156.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- -7.9%
- FCF margin
- 12.5%
- Current ratio
- 2.8x
Growth
- Revenue growth
- +65.2%Latest FY YoY
- Revenue CAGR
- +44.8%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +3.8%3Y annualised
- Net cash
- $1.4B-2.6x OCF
Annual trend
- CAGR 2021–2025
- +44.8%
- Latest · 2025
- $4B
- YoY
- +65.2%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded